[go: up one dir, main page]

UY27675A1 - Combinaciones de un ligado alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2 - Google Patents

Combinaciones de un ligado alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2

Info

Publication number
UY27675A1
UY27675A1 UY27675A UY27675A UY27675A1 UY 27675 A1 UY27675 A1 UY 27675A1 UY 27675 A UY27675 A UY 27675A UY 27675 A UY27675 A UY 27675A UY 27675 A1 UY27675 A1 UY 27675A1
Authority
UY
Uruguay
Prior art keywords
inhibitor
combinations
selective
cyclooxygenasa
alfa
Prior art date
Application number
UY27675A
Other languages
English (en)
Inventor
Charles P Taylor Jr
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY27675A1 publication Critical patent/UY27675A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La invención se refiere a una combinación que comprende un inhibidor selectivo de la COX-2 o una de sus sales farmacéuticamente aceptable y un ligado alfa-2-delta, o una de sus sales farmacéuticamente aceptables, y valdecoxib, y celecoxib. Los ejemplos de los ligados alfa-2-delta incluyen gabapentina, opregaballina, ácido (3S,4S)-(1-aminometil-3,4-dimetil-ciclopentil)-acético, e hidrocloruro de 3.(1- aminometil- ciclohexilmetil)-4H-(1,2,4) oxadiazol-5-ona. Las combinaciones son útiles para tratar ciertas enfermedades que incluyen el dano del cartílago, inflamación, el dolor, y la artritis.
UY27675A 2002-02-22 2003-02-19 Combinaciones de un ligado alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2 UY27675A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35929502P 2002-02-22 2002-02-22
US40436502P 2002-08-19 2002-08-19

Publications (1)

Publication Number Publication Date
UY27675A1 true UY27675A1 (es) 2003-09-30

Family

ID=27760521

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27675A UY27675A1 (es) 2002-02-22 2003-02-19 Combinaciones de un ligado alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2

Country Status (21)

Country Link
US (1) US20030199567A1 (es)
EP (1) EP1480639A1 (es)
JP (1) JP2005523281A (es)
KR (1) KR20040085216A (es)
CN (1) CN1635887A (es)
AR (1) AR038531A1 (es)
AU (1) AU2003246864A1 (es)
BR (1) BR0307906A (es)
CA (1) CA2476438A1 (es)
CO (1) CO5611109A2 (es)
HN (1) HN2003000071A (es)
IL (1) IL162932A0 (es)
MX (1) MXPA04008175A (es)
NO (1) NO20043947L (es)
PA (1) PA8567201A1 (es)
PE (1) PE20031052A1 (es)
PL (1) PL372210A1 (es)
RU (1) RU2286151C2 (es)
TW (1) TW200303214A (es)
UY (1) UY27675A1 (es)
WO (1) WO2003070237A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196201A3 (en) * 2002-12-13 2010-12-08 Warner-Lambert Company LLC Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
PL378583A1 (pl) * 2003-03-21 2006-05-02 Dynogen Pharmaceuticals, Inc. Sposoby leczenia zaburzeń dolnych dróg układu moczowego z zastosowaniem modulatorów mięśni gładkich i modulatorów podjednostki Ó2Ű kanałów wapniowych
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
US7169812B2 (en) 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
ATE449633T1 (de) * 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005041976A2 (en) * 2003-10-23 2005-05-12 Medtronic, Inc. Injectable gabapentin compositions
CL2007001006A1 (es) * 2006-04-11 2008-07-11 Novartis Ag Compuestos derivados de piperidina u 8-aza-biciclo[3.2.1]octano sustituidos; formulacion farmaceutica; producto; y uso para el tratamiento o prevencion de enfermedades tales como diabetes mellitus no insulino dependiente, artritis, obesidad, dislipid
BRPI0718874A2 (pt) * 2006-12-22 2015-06-23 Novartis Ag Compostos orgânicos
EP2286224A4 (en) * 2008-05-05 2012-04-25 Univ Winthrop Hospital METHOD FOR IMPROVING THE CARDIOVASCULAR RISK PROFILE OF COX-INHIBITORS
TR201904388T4 (tr) * 2008-09-05 2019-05-21 Gruenenthal Gmbh Pregabalin veya gabapentin ve 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolün farmasötik kombinasyonu.
KR102631399B1 (ko) * 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
KR20230118081A (ko) * 2020-10-28 2023-08-10 트루모 파마슈티칼스, 인크. 수불용성 cox-2 억제제의 수성 제형

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5352638A (en) * 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
DK0804182T3 (da) * 1994-07-27 2002-09-09 Warner Lambert Co Anvendelse af gabapentin ved behandling af angst og panik
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
BR9812162A (pt) * 1997-09-08 2000-07-18 Warner Lambert Co Composições analgésicas compreendendo compostos antiepiléticos e métodos para o uso das mesmas
NZ503980A (en) * 1997-12-16 2002-09-27 Warner Lambert Co 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (= gabapentin analogues), pharmaceuticals thereof, and their use in the treatment of neurological disorders
AU3216600A (en) * 1999-03-10 2000-09-28 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
HRP20010582A2 (en) * 1999-12-08 2002-08-31 Pharmacia Corp Valdecoxib compositions

Also Published As

Publication number Publication date
TW200303214A (en) 2003-09-01
EP1480639A1 (en) 2004-12-01
RU2004125609A (ru) 2006-01-27
BR0307906A (pt) 2004-12-21
US20030199567A1 (en) 2003-10-23
CN1635887A (zh) 2005-07-06
AU2003246864A1 (en) 2003-09-09
PE20031052A1 (es) 2003-12-24
PL372210A1 (en) 2005-07-11
JP2005523281A (ja) 2005-08-04
RU2286151C2 (ru) 2006-10-27
NO20043947L (no) 2004-09-21
KR20040085216A (ko) 2004-10-07
PA8567201A1 (es) 2003-11-12
CA2476438A1 (en) 2003-08-28
WO2003070237A1 (en) 2003-08-28
CO5611109A2 (es) 2006-02-28
HN2003000071A (es) 2003-11-24
IL162932A0 (en) 2005-11-20
AR038531A1 (es) 2005-01-19
MXPA04008175A (es) 2004-11-26

Similar Documents

Publication Publication Date Title
UY27675A1 (es) Combinaciones de un ligado alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2
PA8592101A1 (es) Nuevos enantiomeros (r) y (s) de derivados del acido tiofeno hidroxamico
AR022023A1 (es) Combinaciones de inhibidores del transporte de acido ileo-biliar con derivados del acido fibrico para prescripciones cardiovasculares
DK1297851T3 (da) Inhibering af histondeacetylasesom behandling af hjertehypertrofi
AR022022A1 (es) Combinaciones de inhibidores del transporte de acido ileo-biliar con agentes secuestrantes de acido biliar, para prescripciones cardiovasculares
AR046970A1 (es) Esteres de fosfato de florfenicol
BRPI0402760A (pt) Composição microbicida
EA200100958A1 (ru) Производные 4,5-диарил-3(2h)-фуранона как ингибиторы циклооксигеназы-2
BR0306675A (pt) Dispositivo para prover um número de produtos
CO2021005070A2 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
MX2021010875A (es) Composiciones de éster de ácido cannabinoide y sus usos.
CL2007002297A1 (es) Medio para enlazar una correa transportadora central de una maquina procesadora de pescado, que comprende un campo de almacenaje intermedio con compartimientos individuales separados por lenguetas o placas y una unidad de segmentos; instalacion y metodo para procesamiento de pescado.
UY28076A1 (es) Procedimiento para aumentar el rendimiento de las leguminosas.
CO2022015630A2 (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
HN2003000040A (es) Acidos 3-(imidazolil)-2-aminopropanoicos
CY1121477T1 (el) Χρηση αλφα-κετογλουταρικου οξεος και 5-υδροξυ-μεθυλοφουρφουραλης για τη μειωση του οξειδωτικου στρες
MXPA04001398A (es) Metodo para el tratamiento y prevencion de dolor e inflamacion con glucosamina y un inhibidor selectivo de ciclooxigenasa-2 y composiciones para el mismo.
BR0011801A (pt) Inibidores de benzamida substituìda para 3c protease de rinovìrus
AR021241A1 (es) Inhibidores de proteasas
AR042037A1 (es) Profarmaco de celecoxib
DOP2003000577A (es) Combinaciones de un ligando alfa-2- delta con un inhibidor selectivo de la ciclooxigenasa-2
MXPA05009902A (es) Formulaciones topicas foto-estabilizadas de ketoprofeno que contienen dos filtros uv.
ES2091031T3 (es) Uso de acido hialuronico para prevenir la reestenosis arterial.
MX2024007050A (es) Metodos y composiciones para mejorar la salud de los animales de compa?ia.
AR012286A1 (es) Ciclopeptolidos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150520